Human Papilloma Virus Testing Market Size, Share, & Trends Analysis Report By Application (Cervical Cancer Screening, Vaginal Cancer Screening), By Product, By Technology, By End Use, By Region, And Segment Forecasts, 2025 - 2030

Market Size & Trends

The global human papilloma virus testing market size was valued at USD 1.76 billion in 2024 and is expected to grow at a CAGR of 13.6% from 2025 to 2030, attributed to increasing awareness of HPV-related cancers, such as cervical and throat cancers. Educational initiatives and public health campaigns encourage people to get tested regularly, leading to higher screening rates.

The adoption of at-home testing kits is further driving market expansion. These kits provide a convenient, private, and accessible method for individuals to test for HPV, empowering users to manage their health more proactively. The combination of heightened awareness and the availability of at-home testing is significantly boosting market demand.

Rising demand for preventive healthcare is projected to fuel the growth of the HPV testing industry, with more individuals seeking early detection to avoid HPV-related cancers. This shift toward proactive health measures encourages routine HPV screenings, especially for women over 30. Technological advancements in testing methods, including PCR-based and next-generation sequencing, are further enhancing the accuracy and efficiency of HPV tests. These innovations make testing more accessible, reliable, and cost-effective, thus driving market expansion by improving the overall patient experience and encouraging broader adoption of HPV testing solutions.

Application Insights

The cervical cancer screening segment dominated the human papilloma virus (HPV) testing industry with the largest revenue share of 76.7% in 2024 due to the high prevalence of HPV-related cervical cancer worldwide. Early detection through HPV testing is essential for preventing the progression of cervical cancer, driving widespread adoption of screening programs. The availability of advanced, noninvasive testing methods, such as HPV DNA tests and liquid-based cytology, has contributed to the segment growth. In addition, increasing awareness of cervical cancer prevention and government initiatives supporting regular screenings further boost demand for HPV testing in cervical cancer detection.

The vaginal cancer screening segment is anticipated to grow at a significant CAGR of 11.8% from 2025 to 2030, owing to the increasing recognition of HPV's role in vaginal cancer development. Rising awareness of HPV-related cancers and improving diagnostic technologies fuel the demand for effective screening methods. Early detection of HPV infections linked to vaginal cancer allows for timely treatment and prevention, reducing cancer risk. The expansion of healthcare infrastructure, particularly in developing regions, and the push for routine screenings are expected to further accelerate the growth of this segment.

Product Insights

The consumables segment accounted for the largest revenue share in 2024, attributed tothe increasing demand for efficient and cost-effective diagnostic solutions. These consumables, such as test kits, reagents, and cartridges, are essential for accurate HPV detection and screening, which is crucial for the prevention of cervical cancer. The growing adoption of HPV testing in routine healthcare and the expansion of testing programs worldwide have further boosted the segment’s growth. Furthermore, the convenience and ease of use offered by consumables have contributed to their widespread adoption in clinical settings.

The services segment is expected to grow at the fastest CAGR during the forecast period, propelled bythe increasing need for specialized testing and counseling services. Healthcare providers expand their offerings to include comprehensive HPV testing solutions, often involving laboratory services, result analysis, and patient education. The rising awareness about HPV-related cancers, along with government initiatives promoting regular screenings, fuels the demand for these services. Moreover, advancements in molecular diagnostics and personalized treatment options are expected to enhance the value and scope of services in HPV testing.

Technology Insights

The PCR segment held the largest revenue share in 2024 due to its high sensitivity and accuracy in detecting HPV DNA. Polymerase Chain Reaction (PCR) allows for the identification of specific viral strains, including high-risk types linked to cervical and other cancers. The technology’s ability to detect low viral loads and provide precise results at early stages of infection has made it the preferred method for HPV testing. Moreover, PCR’s scalability, ease of automation, and ability to test in diverse settings have further fueled its dominance in the human papilloma virus (HPV) testing industry.

The immunodiagnostics segment is projected to grow at a significant CAGR during the forecast period, propelled bythe increasing demand for accurate, reliable, and cost-effective diagnostic solutions. Immunodiagnostic tests, which detect HPV-specific antibodies or antigens, offer advantages such as high sensitivity and faster results. The growing emphasis on preventive healthcare and early detection of HPV-related cancers fuel market growth. In addition, advancements in immunodiagnostic technologies and the expansion of testing infrastructure in emerging markets are expected to significantly contribute to the segment expansion.

End Use Insights

The hospitals & clinics segment held the largest market share in 2024, owing to their central role in providing comprehensive healthcare services. These facilities offer reliable diagnostic testing and follow-up care, making them a primary choice for patients seeking HPV screening. The availability of advanced diagnostic equipment, skilled healthcare professionals, and integrated care systems in hospitals and clinics further contributes to their dominance in the market. Moreover, the increasing number of individuals seeking HPV testing in these settings, driven by awareness campaigns, supports their leading position in the market.

The laboratories segment is expected to experience a significant growth rate during the forecast period, fueled by the increasing demand for accurate, efficient, and reliable testing methods. Advancements in molecular diagnostics, along with the rising awareness of HPV-related health risks, are driving this growth. Laboratories are adopting cutting-edge technologies such as PCR and next-generation sequencing, which enhance the sensitivity and specificity of HPV detection. Furthermore, the growing prevalence of HPV infections and government initiatives promoting HPV testing contribute to the segment’s market potential.

Regional Insights

North America human papilloma virus (HPV) testing market dominated the global market with the largest revenue share of 41.6% in 2024. The integration of HPV testing into routine checkups and the increase in preventive healthcare are driving significant growth in the North America human papilloma virus (HPV) testing industry. Routine screenings for HPV, especially in women, are becoming a standard part of preventive care, helping detect potential risks early. The rising focus on proactive healthcare and disease prevention, along with improved guidelines for cervical cancer screening, boosts the demand for HPV testing. Moreover, healthcare providers are increasingly emphasizing regular testing to identify high-risk strains, further expanding the market size.

U.S. Human Papilloma Virus Testing Market Trends

TheU.S. human papilloma virus (HPV) testing market held the largest share in 2024. The growing demand for home testing kits is expanding the U.S. market by providing individuals with convenient and private options for screening. These at-home kits offer users greater flexibility, leading to increased adoption. In addition, the expansion of HPV vaccination programs is encouraging more people to engage in preventive healthcare, further driving the market. Widespread vaccination efforts reduce the incidence of HPV-related cancers. Still, the need for regular testing remains crucial for ensuring continued growth in demand for HPV diagnostic solutions across the country.

Europe Human Papilloma Virus Testing Market Trends

Europe Human Papilloma Virus (HPV) testing market is anticipated to witness significant expansion over the forecast period, owing to increasing screening initiatives and the rising incidence of cervical cancer. Government-led programs and greater public awareness encourage regular screening, leading to higher demand for HPV tests. The rising number of cervical cancer cases across Europe underscores the importance of early detection, further boosting the market. These efforts foster widespread adoption of HPV testing as a preventive measure, helping reduce cancer risks and driving the overall human papilloma virus (HPV) testing industry expansion in the region.

Asia Pacific Human Papilloma Virus Testing Market Trends

Asia Pacific Human Papilloma Virus (HPV) testing market is set to be the fastest-growing region with a CAGR of 15.5% from 2025 to 2030. This growth can be attributed to the growing focus on women’s health and expanding healthcare access. An increase in awareness of HPV-related cancers and the importance of early detection encourage more women to seek regular screening. Governments and healthcare organizations are investing in awareness campaigns, improving healthcare infrastructure, and making HPV testing more accessible. This heightened emphasis on preventive care and the availability of affordable testing options are set to fuel the demand for HPV testing across the region, driving market growth.

China human papilloma virus (HPV) testing market is projected to grow at the fastest CAGR during the forecast period, driven by the adoption of co-testing and technological advancements. The combination of Pap smear and HPV DNA testing, known as co-testing, is gaining popularity due to its enhanced accuracy in detecting cervical abnormalities and HPV infections. In addition, innovations such as self-collection kits and advanced molecular diagnostic technologies make HPV testing more accessible and efficient. These developments are improving the reliability of results and encouraging more people to undergo regular screening, expanding market size and adoption rates.

Key Human Papilloma Virus Testing Company Insights

Some of the key companies in the human papilloma virus (HPV) testing industry include Abbott, bioMerieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, and Siemens Healthineers AG.

• Abbott offers innovative healthcare solutions, including diagnostic tools, medical devices, nutrition products, and branded generic medicines. The company focuses on improving health and enhancing lives through cutting-edge technology and scientifically backed solutions worldwide.

• bioMérieux specializes in diagnostic solutions, offering a range of products and services for clinical microbiology, molecular biology, and immunoassays. Its solutions help detect infectious diseases, ensuring faster, more accurate diagnoses and better patient outcomes globally.

Recent Developments

• In May 2024, Roche received FDA approval for one of the first HPV self-collection solutions in the U.S. This approval is expected to enhance access to screening and support efforts to eliminate cervical cancer. This solution allows for early detection of HPV, helping identify women at risk and enabling timely treatment to prevent cervical cancer development.

• In February 2025, Metropolis Healthcare, in collaboration with Roche Diagnostics, launched a self-sampling HPV DNA test for cervical cancer screening across India. The test, recognized by the WHO, detects 14 high-risk HPV types and aims to improve access and early detection, particularly in underserved areas.

Human Papilloma Virus Testing Market Report Scope

Global Human Papilloma Virus Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global human papilloma virus (HPV) testing market report on the basis of application, product, technology, end use, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Cervical Cancer Screening

  • Vaginal Cancer Screening

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Instruments

  • Consumables

  • Services

• Technology Outlook (Revenue, USD Million, 2018 - 2030)

  • PCR

  • Immunodiagnostics

  • Others

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals & Clinics

  • Laboratories

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait